Abstract:We investigated the longitudinal changes in cortical tau accumulation and their association with cognitive decline in patients in the Alzheimer disease (AD) continuum using 2-(2-([ 18 F]fluoro)pyridin-4-yl)-9 H -pyrrolo[2,3-b:4,5c']dipyridine ([ 18 F]PI-2620) PET. Methods: We prospectively enrolled 52 participants (age, 69.7 ± 8.4 y; 18 men and 34 women): 7 with normal cognition, 28 with mild cognitive impairment, and 17 with AD. They all completed the [ 18 F]PI-2620 and [ 18 F]florbetaben PET, MRI, and neuropsychologic tests at baseline and, excepting the [ 18 F]florbetaben PET, at the 1-y follow-up. Amyloid-β (Aβ) PET images were visually scored as positive (+) or negative (–). Patients on the AD continuum, including Aβ+ mild cognitive impairment and AD, were classified into early-onset (EO+) (<65 y old) or late-onset (LO+) (≥65 y old) groups. [ 18 F]PI-2620 PET SUV ratios (SUVRs) were determined by calculating the cerebral–to–inferior cerebellar ratio. Cortical volumes were calculated using 3-dimensional T1-weighted MRI. The correlation between tau accumulation progression and cognitive decline was also investigated. Results: The global [ 18 F]PI-2620 PET SUVRs were 1.04 ± 0.07 in 15 Aβ– patients, 1.18 ± 0.21 in 20 LO+ patients (age, 76.7 ± 3.8 y), and 1.54 ± 0.38 in 17 EO+ patients (age, 63.4 ± 5.4 y; P < 0.001) at baseline. The global SUVR increased over 1 y by 0.05 ± 0.07 (3.90%) and 0.13 ± 0.22 (8.41%) in the LO+ and EO+ groups, respectively, whereas in the Aβ– groups, it remained unchanged. The EO+ group showed higher global and regional tau deposition than did the Aβ– and LO+ groups ( P < 0.05 for each) and rapid accumulation in Braak stage V (0.15 ± 0.25; 9.10% ± 12.27%; P = 0.016 and 0.008), Braak stage VI (0.08 ± 0.12; 7.16% ± 10.06%; P < 0.006 and 0.005), and global SUVR ( P = 0.013) compared with the Aβ– group. In the EO+ group, the changes in SUVR in Braak stages II–VI were strongly correlated with the baseline and changes in verbal memory ( P < 0.03). The LO+ group showed higher tau accumulation in Braak stage I–IV areas than did the Aβ– group ( P < 0.001 for each). In the LO+ group, the change in SUVR in Braak stages III and IV moderately correlated with the change in attention ( P < 0.05), and the change in SUVR in Braak stages V and VI moderately correlated with the change in visuospatial function ( P < 0.005). Conclusion: These findings suggest that [ 18 F]PI-2620 PET can be a biomarker to provide regional and chronologic information about tau pathology in the AD continuum.

Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620

Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Neuronal and oligodendroglial but not astroglial tau translates to in vivo tau-PET signals in primary tauopathies

Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain

Parametric Estimation of Reference Signal Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [18F]-APN-1607 Study.

Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer's Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers

In vitro evaluation of [3H]PI-2620 and structural derivatives in non-Alzheimer's tauopathies

Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies

Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings

In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using [18F]PI-2620 PET

Neuroinflammation Parallels 18F‐PI‐2620 Positron Emission Tomography Patterns in Primary 4‐Repeat Tauopathies

International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer’s disease

Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort

PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes

One-Year Longitudinal Changes in Tau Accumulation on [18F]PI-2620 PET in the Alzheimer Spectrum

Linking PI-2620 tau-PET, fluid biomarkers, MRI, and cognition to advance diagnostics for progressive supranuclear palsy

Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer’s Disease

The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease

Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET

18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy